kynurenine has been researched along with Substance-Related Disorders in 3 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Substance-Related Disorders: Disorders related to substance use or abuse.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We review the literature concerning SARS-CoV2 infiltration and infection in the CNS and the prospects of synergy between stress, inflammation, and kynurenine pathway function during illness and recovery from Covid-19." | 5.12 | Covid-19 interface with drug misuse and substance use disorders. ( Cisneros, IE; Cunningham, KA, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Z | 1 |
| Zhang, M | 1 |
| Luo, Y | 1 |
| Ni, X | 1 |
| Lu, H | 1 |
| Wen, Y | 1 |
| Fan, N | 1 |
| Lee, J | 1 |
| Lee, JY | 1 |
| Meade, CS | 1 |
| Cohn, M | 1 |
| Chahine, A | 1 |
| Dilworth, SE | 1 |
| Magidson, JF | 1 |
| Gouse, H | 1 |
| Fuchs, D | 1 |
| Carrico, AW | 1 |
| Cisneros, IE | 1 |
| Cunningham, KA | 1 |
1 review available for kynurenine and Substance-Related Disorders
| Article | Year |
|---|---|
Covid-19 interface with drug misuse and substance use disorders.
Topics: Adaptation, Psychological; Angiotensin-Converting Enzyme 2; Animals; Axons; Comorbidity; COVID-19; D | 2021 |
2 other studies available for kynurenine and Substance-Related Disorders
| Article | Year |
|---|---|
Preliminary comparative analysis of kynurenine pathway metabolites in chronic ketamine users, schizophrenic patients, and healthy controls.
Topics: Adult; Case-Control Studies; Chromatography, High Pressure Liquid; Female; Humans; Ketamine; Kynuren | 2020 |
Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biotransformation; Cross-Sectional St | 2020 |